Document Detail


Protease-activated receptor-2 activation exaggerates TRPV1-mediated cough in guinea pigs.
MedLine Citation:
PMID:  16627674     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A lowered threshold to the cough response frequently accompanies chronic airway inflammatory conditions. However, the mechanism(s) that from chronic inflammation results in a lowered cough threshold is poorly understood. Irritant agents, including capsaicin, resiniferatoxin, and citric acid, elicit cough in humans and in experimental animals through the activation of the transient receptor potential vanilloid 1 (TRPV1). Protease-activated receptor-2 (PAR2) activation plays a role in inflammation and sensitizes TRPV1 in cultured sensory neurons by a PKC-dependent pathway. Here, we have investigated whether PAR2 activation exaggerates TRPV1-dependent cough in guinea pigs and whether protein kinases are involved in the PAR2-induced cough modulation. Aerosolized PAR2 agonists (PAR2-activating peptide and trypsin) did not produce any cough per se. However, they potentiated citric acid- and resiniferatoxin-induced cough, an effect that was completely prevented by the TRPV1 receptor antagonist capsazepine. In contrast, cough induced by hypertonic saline, a stimulus that provokes cough in a TRPV1-independent manner, was not modified by aerosolized PAR2 agonists. The PKC inhibitor GF-109203X, the PKA inhibitor H-89, and the cyclooxygenase inhibitor indomethacin did not affect cough induced by TRPV1 agonists, but abated the exaggeration of this response produced by PAR2 agonists. In conclusion, PAR2 stimulation exaggerates TRPV1-dependent cough by activation of diverse mechanism(s), including PKC, PKA, and prostanoid release. PAR2 activation, by sensitizing TRPV1 in primary sensory neurons, may play a role in the exaggerated cough observed in certain airways inflammatory diseases such as asthma and chronic obstructive pulmonary disease.
Authors:
Raffaele Gatti; Eunice Andre; Silvia Amadesi; Thai Q Dinh; Axel Fischer; Nigel W Bunnett; Selena Harrison; Pierangelo Geppetti; Marcello Trevisani
Related Documents :
8782884 - Vanilloid receptor loss is independent of the messenger plasticity that follows systemi...
12687684 - Primary afferent terminals that express presynaptic nr1 in rats are mainly from myelina...
12921864 - Cannabinoid cb1 receptor inhibition of mechanically evoked responses of spinal neurones...
21376464 - Attenuation of pain-related behavior evoked by injury through blockade of neuropeptide ...
7320814 - The cytochemical demonstration of oestrogen receptors in human breast carcinomas.
12627954 - Regulation of epidermal growth factor receptor internalization by g protein-coupled rec...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2006-04-20
Journal Detail:
Title:  Journal of applied physiology (Bethesda, Md. : 1985)     Volume:  101     ISSN:  8750-7587     ISO Abbreviation:  J. Appl. Physiol.     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-07-19     Completed Date:  2006-09-12     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8502536     Medline TA:  J Appl Physiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  506-11     Citation Subset:  IM    
Affiliation:
Center of Excellence for the study of Inflammation, Dept. of Clinical & Experimental Medicine, Pharmacology Section, Univ. of Ferrara, 44100 Ferrara, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Capsaicin / analogs & derivatives,  pharmacology
Citric Acid / adverse effects
Cough / chemically induced,  physiopathology*
Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors,  physiology
Cyclooxygenase Inhibitors / pharmacology
Diterpenes / adverse effects
Guinea Pigs / physiology*
Indomethacin / pharmacology
Inflammation
Isoquinolines / pharmacology
Male
Neurons, Afferent / physiology
Protein Kinase C / antagonists & inhibitors,  physiology
Protein Kinase Inhibitors / pharmacology
Receptor, PAR-2 / physiology*
Saline Solution, Hypertonic / adverse effects
Sulfonamides / pharmacology
TRPV Cation Channels / physiology*
Trypsin / pharmacology
Grant Support
ID/Acronym/Agency:
DK-43207/DK/NIDDK NIH HHS; DK-57480/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Cyclooxygenase Inhibitors; 0/Diterpenes; 0/Isoquinolines; 0/Protein Kinase Inhibitors; 0/Receptor, PAR-2; 0/Saline Solution, Hypertonic; 0/Sulfonamides; 0/TRPV Cation Channels; 0/capsazepine; 127243-85-0/H 89; 404-86-4/Capsaicin; 53-86-1/Indomethacin; 57444-62-9/resiniferatoxin; 77-92-9/Citric Acid; EC 2.7.11.11/Cyclic AMP-Dependent Protein Kinases; EC 2.7.11.13/Protein Kinase C; EC 3.4.21.4/Trypsin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Increased propensity for apnea in response to acute elevations in left atrial pressure during sleep ...
Next Document:  Effects of chronic NaHCO3 ingestion during interval training on changes to muscle buffer capacity, m...